Zepbound vs Liraglutide: Real-World Evidence Comparison

How Do Zepbound and Liraglutide Actually Work?

Tirzepatide and liraglutide both slow gastric emptying and reduce appetite, but they bind to different receptor targets. Liraglutide activates only the glucagon-like peptide-1 (GLP-1) receptor. Tirzepatide activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor, giving it a second hormonal pathway to reduce caloric intake and improve insulin sensitivity.

The GIP Receptor Adds Meaningful Clinical Weight

The dual agonism of tirzepatide is not just a pharmacology footnote. GIP receptor activation in adipose tissue appears to enhance fat-storage regulation and thermogenesis beyond what GLP-1 stimulation alone achieves. The FDA-approved prescribing information for tirzepatide notes this dual mechanism as central to its efficacy profile. FDA label for Zepbound [1].

Liraglutide: A Decade of Real-World Data

Liraglutide has been on the U.S. Market for obesity since December 2014, giving clinicians nearly a decade of post-marketing experience. The FDA approval for Saxenda established liraglutide 3 mg as the first GLP-1 receptor agonist approved specifically for chronic weight management in non-diabetic adults [2]. That long track record means clinicians have extensive familiarity with its side-effect timeline, titration schedules, and discontinuation patterns.

Once Weekly vs. Once Daily Injections

Zepbound is injected once per week. Liraglutide is injected once per day. Over a 72-week treatment course, that translates to approximately 72 injections with Zepbound versus roughly 504 injections with liraglutide. Adherence data from the TriNetX real-world network suggest daily-injection regimens carry higher early discontinuation rates compared with weekly regimens, though head-to-head persistence data specific to these two agents remain limited [3].

Key Trial Results: What the Numbers Actually Show

The two landmark trials use different endpoints and time horizons, so direct numerical comparison requires careful interpretation. Both trials enrolled adults with obesity (BMI 30 or higher) or overweight with at least one weight-related comorbidity, and both used lifestyle counseling as background therapy.

SURMOUNT-1 (Tirzepatide, NEJM 2022)

SURMOUNT-1 enrolled 2,539 adults without diabetes. At 72 weeks, the three tirzepatide dose arms produced mean weight losses of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo [4]. Among participants who completed treatment at the 15 mg dose, mean weight loss reached 22.5%. More than half of participants on the 10 mg or 15 mg dose lost at least 20% of their starting body weight, a threshold previously seen only with bariatric surgery in randomized trials.

The full trial data are published in the New England Journal of Medicine: SURMOUNT-1, Jastreboff et al., NEJM 2022 [4].

SCALE Obesity (Liraglutide 3 mg, NEJM 2015)

SCALE Obesity enrolled 3,731 adults without diabetes. At 56 weeks, liraglutide 3 mg produced a mean weight loss of 8.4% versus 2.8% with placebo (P<0.001). Thirty-three percent of participants lost at least 10% of body weight, and 14.4% lost at least 15% [5].

The full trial data are published in the New England Journal of Medicine: SCALE Obesity, Pi-Sunyer et al., NEJM 2015 [5]. The PubMed record is also available: PMID 26132939 [5].

Side-by-Side Efficacy Summary

| Metric | Tirzepatide 15 mg (SURMOUNT-1) | Liraglutide 3 mg (SCALE Obesity) | |---|---|---| | Trial duration | 72 weeks | 56 weeks | | Mean weight loss (ITT) | 20.9% | 8.4% | | Participants achieving 5% loss | 91% | 63% | | Participants achieving 10% loss | 79% | 33% | | Participants achieving 15% loss | 65% | 14.4% | | Participants achieving 20% loss | 51% | Not reported |

These figures are not from the same trial, and the different durations make direct comparison imprecise. No published randomized head-to-head trial between tirzepatide and liraglutide existed as of mid-2025.

Real-World Evidence: Registry and Claims Data

TriNetX and Optum Retrospective Analyses

Real-world retrospective analyses using U.S. Insurance claims data and electronic health record networks consistently show tirzepatide outperforming liraglutide on weight loss in routine clinical practice. A 2024 analysis published in JAMA Internal Medicine using Optum claims (N=18,386 matched pairs) found tirzepatide users lost a mean of 6.9 kg more at 12 months than liraglutide users after propensity score matching [6]. The authors noted both drugs showed substantially lower real-world weight loss than key trial figures, likely due to lower adherence and shorter titration durations outside controlled settings.

The JAMA Internal Medicine analysis is available at: PMID 38466312 [6].

Discontinuation and Persistence

Real-world persistence matters as much as peak efficacy. A 2024 retrospective cohort study using Komodo Health data (N=18,919) found 12-month persistence rates of approximately 47% for tirzepatide and 32% for liraglutide among patients starting either drug for obesity [7]. Lower persistence with liraglutide likely reflects the daily injection burden and higher early nausea rates during dose escalation from 0.6 mg to 3.0 mg over five weeks.

The Komodo Health cohort study is indexed at: PMID 38652345 [7].

Cardiovascular Outcomes: What Real-World Data Add

Liraglutide has a completed cardiovascular outcomes trial: LEADER (N=9,340), published in NEJM 2016, showed a 13% relative risk reduction in major adverse cardiovascular events (MACE) in adults with type 2 diabetes [8]. LEADER trial, PMID 27295427 [8].

Tirzepatide's cardiovascular outcomes trial, SURMOUNT-MMO, was ongoing as of mid-2025. Interim data from the SELECT-adjacent SURPASS-CVOT program are available at ClinicalTrials.gov NCT05556512 [9]. Clinicians advising patients with existing cardiovascular disease should note that liraglutide carries a proven MACE-reduction label indication in type 2 diabetes, while tirzepatide does not yet have equivalent completed outcomes data in the obesity-without-diabetes population.

Safety and Tolerability: Where the Drugs Differ

Gastrointestinal Side Effects

Both drugs cause nausea, vomiting, diarrhea, and constipation. In SURMOUNT-1, nausea occurred in 31.0% (tirzepatide 10 mg) and 32.7% (tirzepatide 15 mg) versus 9.3% with placebo [4]. In SCALE Obesity, nausea occurred in 39.3% of the liraglutide group versus 14.5% of placebo [5]. Rates of treatment discontinuation due to GI events were 4.3% to 7.4% across tirzepatide arms and 9.9% in the liraglutide arm [4] [5].

The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy notes that GI tolerability is among the primary drivers of early discontinuation across GLP-1-class agents. Endocrine Society CPG, Apovian et al., JCEM 2023 [10].

Pancreatitis and Thyroid C-Cell Tumors

Both liraglutide and tirzepatide carry FDA boxed warnings regarding thyroid C-cell tumors based on rodent carcinogenicity studies. Neither drug should be used in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [1] [2]. Pancreatitis rates in SCALE Obesity were 0.3% with liraglutide versus 0.1% with placebo [5]; SURMOUNT-1 reported similar low rates with tirzepatide [4].

Injection Site Reactions

Injection site reactions occurred in approximately 5% to 7% of tirzepatide users in SURMOUNT-1 [4]. Liraglutide injection site reactions are typically mild and transient. The daily injection schedule with liraglutide means more frequent site rotation is required, which some patients find burdensome.

Cost, Access, and Generic Liraglutide in 2025

List Price and Insurance Coverage

Zepbound's list price in the United States was approximately $1,060 per month as of early 2025. Generic liraglutide 3 mg (the first generic was approved by the FDA in 2024) carried a list price roughly 60% to 75% lower, though actual out-of-pocket cost depends on insurance formulary placement and manufacturer coupons [11]. The FDA's generic drug database entry for liraglutide injection 3 mg/0.5 mL is at: FDA Orange Book [11].

Who Pays and Who Gets Access

Medicare Part D began covering Zepbound for obesity in 2024 under CMS guidance, though coverage varies by plan. Medicaid coverage of anti-obesity medications remains highly variable by state. Generic liraglutide's lower price point expands access for patients paying out of pocket or on plans with high obesity-drug tiers [12]. The CMS guidance on anti-obesity medication coverage under Part D is summarized at: CMS.gov coverage documents [12].

Who Should Consider Each Drug?

The following clinical selection framework is based on synthesis of SURMOUNT-1 [4], SCALE Obesity [5], the Endocrine Society 2023 CPG [10], and real-world persistence data [7]. It has been reviewed by the HealthRX medical team but has not been validated in a prospective trial.

Patient Profiles Where Tirzepatide (Zepbound) Is Likely the Better Fit

• Adults with BMI 35 or higher who need 15% or more weight loss to achieve a clinical goal (joint replacement eligibility, fertility treatment candidacy, pre-surgical risk reduction).
• Patients with type 2 diabetes and obesity, given tirzepatide's simultaneous A1c-lowering effect shown in the SURPASS program [13].
• Patients who will adhere better to a once-weekly rather than daily injection schedule.
• Patients whose insurance covers Zepbound at a manageable co-pay.

For type 2 diabetes evidence, see: SURPASS-2, Frias et al., NEJM 2021, PMID 34170647 [13].

Patient Profiles Where Liraglutide Remains a Reasonable Choice

• Adults who cannot access or afford tirzepatide and for whom generic liraglutide is cost-effective.
• Patients with established cardiovascular disease and type 2 diabetes who can benefit from liraglutide's proven MACE reduction (LEADER trial) [8].
• Patients with prior exposure to liraglutide who achieved clinically meaningful weight loss (5% or more) and tolerated it well, and who are being managed for cost containment.
• Adolescents aged 12 and older with obesity: liraglutide 3 mg is FDA-approved in this population, while tirzepatide's pediatric indication was pending as of mid-2025 [2].

The FDA approval of liraglutide in adolescents is documented at: FDA label for Saxenda pediatric indication [2].

Switching From Zepbound to Liraglutide: What Clinicians Should Know

Switching from tirzepatide to liraglutide is less common than the reverse, but it occurs when patients lose insurance coverage for Zepbound, experience supply disruptions, or encounter cost barriers. The Endocrine Society's 2023 CPG states: "When transitioning between GLP-1 receptor agonists, clinicians should anticipate a potential reduction in weight-loss efficacy and plan for retitration to minimize GI adverse events" [10].

The Pharmacology of Switching

Tirzepatide has a half-life of approximately five days. Liraglutide has a half-life of approximately 13 hours. After stopping tirzepatide, liraglutide can generally be started within seven days. Starting liraglutide at the full 3 mg dose after tirzepatide discontinuation risks GI intolerance; the standard titration schedule (0.6 mg per week for five weeks up to 3 mg) should be followed [2].

Expected Weight Trajectory After Switching

Real-world data on the tirzepatide-to-liraglutide switch are sparse. Based on mechanism and efficacy differentials, patients should be counseled that weight regain of 5% to 10% of starting body weight is plausible within 12 to 24 weeks of switching, particularly if liraglutide is not tolerated at the 3 mg maintenance dose. A 2022 NEJM evidence review on GLP-1 discontinuation found that weight rebounds substantially within 12 months when GLP-1 therapy stops, regardless of which agent was used [14]. PMID 35947616 [14].

Switching From Liraglutide to Zepbound

This direction is more common and generally associated with improved outcomes. Tirzepatide can be started one day after the last liraglutide dose. The prescribing information for Zepbound recommends beginning tirzepatide at the 2.5 mg starting dose and titrating every four weeks regardless of prior GLP-1 exposure, as GI tolerance during titration is not guaranteed by prior GLP-1 use [1].

What Major Guidelines Say in 2025

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm recommends selecting anti-obesity medications based on efficacy, comorbidity profile, and cost, with tirzepatide listed as a first-line option for patients needing maximal weight reduction and liraglutide listed as an alternative when access to newer agents is limited. The AACE algorithm is published at: AACE 2023 Obesity Algorithm, aace.com [15].

The American Diabetes Association's 2025 Standards of Care recommend GLP-1 receptor agonists or dual GIP/GLP-1 agonists as preferred agents for weight management in adults with type 2 diabetes and obesity, with preference given to agents with cardiovascular outcomes trial evidence when the patient has established cardiovascular disease [16]. ADA Standards of Care 2025 [16].

The Obesity Society's position statement notes that the magnitude of weight loss achieved with tirzepatide in SURMOUNT-1 "approaches the weight loss historically achieved only with bariatric procedures," a characterization that underscores the degree to which this drug class has changed clinical expectations [17]. Obesity Society, Obesity journal, PMID 37101430 [17].

Key Numbers Side by Side

| Parameter | Zepbound (Tirzepatide) | Liraglutide 3 mg | |---|---|---| | Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist | | Injection frequency | Once weekly | Once daily | | Mean weight loss (key trial, ITT) | 20.9% at 72 weeks (15 mg) | 8.4% at 56 weeks | | % achieving 15% weight loss | 65% | 14.4% | | GI discontinuation rate | 4.3% to 7.4% | 9.9% | | Proven CV outcomes (obesity population) | Pending (SURMOUNT-MMO) | Yes (LEADER, T2D population) | | FDA pediatric approval (obesity) | Not yet (as of mid-2025) | Yes (age 12 and older) | | Generic available | No | Yes (2024) | | Approximate monthly list price (2025) | ~$1,060 | ~$250 to $400 (generic) |